English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

S-carboxymethyl-L-cysteine (carbocisteine, SCMC) is a mucoregulating drug with a normalizing effect on airway mucus and a repairing effect on mucosa. The drug is used in a wide range of age groups, from infants to elderly patients. SCMC has chronopharmacological characteristics, i.e. its metabolic pathway and metabolites vary according to the time of day when the drug is orally ingested (1, 2). Thiodiglycolic acid (TDA), a metabolite produced during the night, has been assumed to be a component responsible for fixed drug eruption (FDE) associated with SCMC (3). This report presents a case of SCMC-induced FDE in which an oral challenge test induced a skin eruption following oral administration of SCMC in the evening only for 2 days.

S-Carboxymethyl-L-cysteine-induced Fixed Drug Eruption